Sipuleucel-t - Biologic Drug Details

Summary for sipuleucel-t

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for sipuleucel-t

Recent Clinical Trials for sipuleucel-t

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
City of Hope Medical Center	PHASE1
National Cancer Institute (NCI)	PHASE1
Case Comprehensive Cancer Center	PHASE2

See all sipuleucel-t clinical trials

Pharmacology for sipuleucel-t

Physiological Effect	Cell-mediated Immunity
Established Pharmacologic Class	Autologous Cellular Immunotherapy
Chemical Structure	Leukocytes, Mononuclear

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for sipuleucel-t Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for sipuleucel-t Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2018-09-03	DrugPatentWatch analysis and company disclosures
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2019-06-24	DrugPatentWatch analysis and company disclosures
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2022-04-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for sipuleucel-t Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2036-01-12	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2034-12-01	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2034-12-01	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2034-12-12	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2037-03-03	Patent claims search
Dendreon Pharmaceuticals Llc	PROVENGE	sipuleucel-t	Injection	125197		2034-09-05	Patent claims search

Market Dynamics and Financial Trajectory for Sipuleucel-T

Last updated: February 27, 2026

What Drives the Market for Sipuleucel-T?

Sipuleucel-T, marketed as Provenge, is an autologous cellular immunotherapy approved for metastatic castration-resistant prostate cancer (mCRPC). Since its FDA approval in 2010, its market position has been shaped by several factors:

• FDA approval date: April 2010
• Indication: Asymptomatic or minimally symptomatic metastatic hormone-refractory prostate cancer
• Pricing: Approximate list price around $93,000 per treatment course (per 2010 approval data), with recent adjustments depending on healthcare negotiations
• Market penetration: Limited due to the high cost, complex administration process, and emergence of competing therapies
• Competitive landscape: Checkpoint inhibitors, novel hormonal agents, and chemotherapy options have gained ground, reducing market share

How Does the Market Size Evolve for Sipuleucel-T?

Estimated global sales figures reflect its niche status. Based on industry reports, 2020 sales were roughly $12 million, with a gradual increase expected due to:

• Increased adoption in the U.S.
• Expansion into new healthcare settings
• Reimbursement policy adjustments

By 2022, sales increased marginally to approximately $15 million, with projections indicating slow growth. The drug's market is constrained by:

• Limited indications restricted to specific patient populations
• High treatment cost and complex logistics involved in autologous cell collection and processing
• Competition from alternative treatments

What Are the Key Factors Affecting Financial Trajectory?

R&D and Regulatory Landscape

• Ongoing trials exploring sipuleucel-T in earlier stages of prostate cancer or combination therapies could expand its indications.
• Regulatory agencies may impose additional requirements for reimbursement and surveillance, impacting market access.

Market Entry Barriers

• Manufacturing costs remain high due to personalized processing
• Reimbursement policies vary, impacting profitability
• Manufacturers have explored biosimilars, but no biosimilars for sipuleucel-T are currently approved or in late-stage development

Competition and Novel Therapies

• Pembrolizumab (Keytruda) and other immunotherapies demonstrate efficacy in prostate cancer, potentially encroaching on sipuleucel-T’s niche
• New hormonal and chemotherapeutic agents with better efficacy and convenience reduce demand

Pricing and Reimbursement Trends

• Increasing pressure to lower healthcare costs may lead to price reductions
• CMS and private insurers scrutinize high-cost therapies more rigorously
• Value-based agreements and outcomes-based reimbursement arrangements are emerging

Manufacturing and Supply Chain Dynamics

• Automating the process may lower costs over time but requires substantial capital investments
• Supply chain disruptions could impede production scalability

Financial Outlook and Projections

Year	Estimated US Sales (Million USD)	Comments
2020	$12	Steady but limited sales volume
2022	$15	Slight growth, driven by increased approval in some settings
2025+	$20–25	Potential growth if expanded indications or combination therapies gain approval

Long-term growth hinges on:

• Development of combination regimens with checkpoint inhibitors
• Approval for earlier disease stages
• Reduction in manufacturing costs helping decrease price barriers

Summary of Market Challenges & Opportunities

Challenges	Opportunities
Limited indications	Expanding to earlier prostate cancer stages
High treatment costs	Developing cost-effective manufacturing methods
Competition from emerging therapies	Combining with novel immunotherapies
Market access restrictions	Value-based reimbursement programs

Key Takeaways

• Sipuleucel-T remains a niche immunotherapy with limited growth prospects outside expanded indications
• Market size persists due to slow adoption, high costs, and competition from other therapies
• Financial trajectory predicts modest growth through 2025, contingent on regulatory approvals, demonstration of value, and manufacturing efficiencies
• Commercial success depends heavily on payer acceptance and ability to lower costs

FAQs

1. How does sipuleucel-T compare to other prostate cancer treatments?
Compared to chemotherapy and hormonal therapies, sipuleucel-T offers a novel immunotherapeutic approach targeting early metastatic states. It has shown survival benefits but is less commonly used due to cost and logistic complexities.

2. What are the main barriers to wider adoption?
High cost, complex manufacturing process, limited patient eligibility, and competition from newer therapies hinder wider market adoption.

3. Will biosimilars impact the market for sipuleucel-T?
No biosimilars are currently approved or in late development; the personalized nature of the product complicates biosimilar development.

4. Are there regulatory efforts to expand sipuleucel-T’s indications?
Ongoing trials explore use in earlier stages of prostate cancer, which could expand its label if successful. Such approvals would significantly impact market size.

5. What is the outlook for the long-term profitability of sipuleucel-T?
Profitability will depend on market expansion, cost management, and payer acceptance. Limited growth prospects suggest a cautious outlook absent significant indication expansion.

---

References

[1] U.S. Food and Drug Administration. (2010). FDA approves prostate cancer immunotherapy. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-prostate-cancer-immunotherapy

[2] IMS Health. (2020). Global Oncology Drug Sales.

[3] Prostate Cancer Foundation. (2022). Market Analysis of Immunotherapies.

[4] National Comprehensive Cancer Network. (2022). Prostate Cancer Guidelines.

[5] EvaluatePharma. (2023). Oncology Market Trends.